Allergan plc (NYSE:AGN) was the recipient of unusually large options trading activity on Friday. Traders purchased 8,889 put options on the stock. This represents an increase of approximately 347% compared to the typical volume of 1,990 put options.
Allergan plc (NYSE:AGN) last announced its quarterly earnings data on Tuesday, May 9th. The company reported $3.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.32 by $0.03. Allergan plc had a return on equity of 7.21% and a net margin of 100.04%. The firm had revenue of $3.57 billion during the quarter, compared to analysts’ expectations of $3.53 billion. During the same period last year, the business posted $3.04 earnings per share. The company’s revenue for the quarter was up 5.1% compared to the same quarter last year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 15th. Stockholders of record on Thursday, May 18th will be paid a $0.70 dividend. This represents a $2.80 annualized dividend and a dividend yield of 1.28%. The ex-dividend date of this dividend is Tuesday, May 16th.
In related news, Director Paul Bisaro sold 70,000 shares of the stock in a transaction dated Thursday, March 2nd. The shares were sold at an average price of $246.68, for a total transaction of $17,267,600.00. Following the completion of the transaction, the director now owns 274,226 shares in the company, valued at $67,646,069.68. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 0.27% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in AGN. Crestwood Advisors Group LLC purchased a new position in shares of Allergan plc during the first quarter valued at about $103,000. Sunbelt Securities Inc. bought a new position in shares of Allergan plc during the fourth quarter valued at $107,000. Feltz Wealth PLAN Inc. bought a new position in shares of Allergan plc during the first quarter valued at $107,000. Enterprise Financial Services Corp boosted its position in shares of Allergan plc by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock valued at $110,000 after buying an additional 178 shares in the last quarter. Finally, JNBA Financial Advisors boosted its position in shares of Allergan plc by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after buying an additional 12 shares in the last quarter. Hedge funds and other institutional investors own 86.40% of the company’s stock.
Several equities analysts recently weighed in on the stock. Royal Bank of Canada set a $279.00 price target on shares of Allergan plc and gave the company a “buy” rating in a research report on Tuesday, February 14th. Credit Suisse Group AG reiterated a “buy” rating and set a $274.00 target price on shares of Allergan plc in a research report on Tuesday, February 14th. Piper Jaffray Companies set a $205.00 target price on shares of Allergan plc and gave the stock a “hold” rating in a research report on Wednesday, February 22nd. Vetr upgraded shares of Allergan plc from a “hold” rating to a “buy” rating and set a $256.33 target price for the company in a research report on Wednesday, March 1st. Finally, Leerink Swann increased their target price on shares of Allergan plc to $280.00 and gave the stock a “buy” rating in a research report on Thursday, February 9th. Six equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $267.21.
Allergan plc Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan plc and related companies with MarketBeat.com's FREE daily email newsletter.